FILANA THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
FLNA$0.48-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| Years ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows from operating activities: | |||
| Net loss | $(90,973) | $(24,342) | $(97,217) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation | 19,582 | 16,291 | 4,586 |
| Gain from change in fair value of warrant liabilities | — | (108,183) | — |
| Depreciation | 903 | 952 | 1,084 |
| Amortization of intangible assets | 33 | 180 | 446 |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | 6,080 | 539 | 1,714 |
| Operating lease right-of-use assets and liabilities | — | — | (17) |
| Accounts payable and other accrued expenses | 33,993 | (2,919) | 6,896 |
| Accrued development expense | (2,076) | (597) | 757 |
| Accrued compensation and benefits | 268 | 1,157 | 30 |
| Other liabilities | (62) | (7) | (304) |
| Net cash used in operating activities | (32,252) | (116,929) | (82,025) |
| Cash flows from investing activities: | |||
| Purchases of property and equipment | (581) | (103) | (414) |
| Net cash used in investing activities | (581) | (103) | (414) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common stock upon exercise of stock options | 90 | 918 | 2,560 |
| Proceeds from exercise of common stock warrants, net of exercise costs | — | 123,552 | — |
| 2025 ATM offering program costs | (329) | — | — |
| Net cash (used in) / provided by financing activities | (239) | 124,470 | 2,560 |
| Net increase (decrease) in cash and cash equivalents | (33,072) | 7,438 | (79,879) |
| Cash and cash equivalents at beginning of period | 128,574 | 121,136 | 201,015 |
| Cash and cash equivalents at end of period | $95,502 | $128,574 | $121,136 |
| Supplemental cash flow information: | |||
| Non-cash financing activities | |||
| Issuance of warrants resulting in recognition of warrant liabilities | — | 113,363 | — |
| Derecognition of warrant liabilities upon exercise of warrants | — | (5,180) | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.